Impact of the COVID-19 pandemic on access to the cerliponase alfa managed access agreement in England for CLN2 treatment

BACKGROUND: Cerliponase alfa, an enzyme replacement therapy for neuronal ceroid lipofuscinosis type 2 (CLN2), is currently available in England through a managed access agreement (MAA). It is administered every 2 weeks via an intracerebroventricular device. Here we report qualitative research with f...

Descripción completa

Detalles Bibliográficos
Autores principales: Mortensen, Amanda, Raebel, Eva M., Wiseman, Samantha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8767529/
https://www.ncbi.nlm.nih.gov/pubmed/35045884
http://dx.doi.org/10.1186/s13023-021-02147-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8767529/
https://www.ncbi.nlm.nih.gov/pubmed/35045884
http://dx.doi.org/10.1186/s13023-021-02147-y

Ejemplares similares